Edwards Lifesciences Corporation (NYSE: EW: 67.43, n.a., n.a.%), the global leader in the science of heart valves 
and hemodynamic monitoring, today announced the opening of its new regional headquarters in Nyon, Switzerland. The facility will serve Edwards' growing Europe, Middle East and Africa (EMEA) operations from a more central location, and features a state-of-the-art training facility where physicians can educate their peers on new technologies and techniques that have the potential to drive better outcomes and lower costs. "Edwards' new headquarters will help us accommodate our significant regional growth in heart valves and critical care, and allow us to continue benefiting from a favorable business climate," said Patrick B. Verguet, Edwards' corporate vice president, Europe, Middle East and Africa. "We look forward to expanding our commitment to training and education programs by welcoming physicians and healthcare professionals to our new facility." "We are pleased to welcome the global cardiovascular and critical care technology innovator Edwards Lifesciences to Nyon. The city's economy will benefit from not only the operation of the headquarters here, but also the visitors Edwards expects for meetings and trainings at the new building," said Daniel Rossellat, Syndic of Nyon. "The Canton de Vaud has established a strong presence of leading companies like Edwards, and we look forward to the additional job and economic development opportunities that will result from a thriving bio-medical industry in this region. We are encouraged that companies like Edwards are continuing to recruit new talent, even during a challenging global economy," said Philippe Leuba, Conseiller d'Etat of Canton de Vaud.
and hemodynamic monitoring, today announced the opening of its new regional headquarters in Nyon, Switzerland. The facility will serve Edwards' growing Europe, Middle East and Africa (EMEA) operations from a more central location, and features a state-of-the-art training facility where physicians can educate their peers on new technologies and techniques that have the potential to drive better outcomes and lower costs. "Edwards' new headquarters will help us accommodate our significant regional growth in heart valves and critical care, and allow us to continue benefiting from a favorable business climate," said Patrick B. Verguet, Edwards' corporate vice president, Europe, Middle East and Africa. "We look forward to expanding our commitment to training and education programs by welcoming physicians and healthcare professionals to our new facility." "We are pleased to welcome the global cardiovascular and critical care technology innovator Edwards Lifesciences to Nyon. The city's economy will benefit from not only the operation of the headquarters here, but also the visitors Edwards expects for meetings and trainings at the new building," said Daniel Rossellat, Syndic of Nyon. "The Canton de Vaud has established a strong presence of leading companies like Edwards, and we look forward to the additional job and economic development opportunities that will result from a thriving bio-medical industry in this region. We are encouraged that companies like Edwards are continuing to recruit new talent, even during a challenging global economy," said Philippe Leuba, Conseiller d'Etat of Canton de Vaud.
